ErebaGen is delighted to announce the appointment of Bernd Gerhartz to our Board, and to re-introduce David Williams, who joined our Board in January 2024. With decades of extensive experience across the biotechnology sector and several focused pharma projects, we are excited to gather their insights to support ErebaGen’s mission, to discover, optimise and scale truly novel bioactive products from microbes.
Bernd brings over 30 years of protein biochemistry expertise, accrued through his career at Novartis, Abcam, and Better Dairy, alongside a strong track record of successful patent applications. As a national and international leader, his experience of building teams from the ground up will help us to navigate the next stage of our development.
Speaking of his recent appointment, Bernd said, “I am excited to join ErebaGen, I believe the technology platform has the potential to revolutionise current production processes in chemical manufacturing.”
As a founder of several successful biotech companies, David offers significant expertise in business and research and development strategy, as well as commercial business development. He has successfully managed exits for investors and brings invaluable experience of maximising investment opportunities, with deals totalling $5bn across pharma and biotech.
David reflects on his time with ErebaGen so far, commenting, “I’ve enjoyed working with the team on what we believe could be a truly transformational platform for the chemical industry – both in the discovery and manufacturing sectors – and look forward to an exciting commercial journey”.
ErebaGen investor, Start Codon, commented: “It’s great to see ErebaGen building out its Board with experts who bring a mix of entrepreneurial, commercial and scientific skills and experience. We’re excited to see what comes next for the team.”
The ErebaGen team is looking forward to working with both Bernd and David to drive us towards our goals.